The global generic injectables market value was USD 101.3 billion in 2022, driven by the increasing demand for affordable healthcare across the globe. The market size is anticipated to grow at a CAGR of 13% during the forecast period of 2023-2031 to achieve a value of USD 305.5 billion by 2031.
The market is driven by several factors, including the increasing demand for affordable healthcare solutions, the expiration of patents for widely-used injectable drugs, and government initiatives promoting the use of generic medications. Healthcare providers and payers are actively seeking cost-saving measures, and generic injectables provide significant savings without compromising patient care.
Overall, the market for generic injectables is driven by the increasing demand for affordable healthcare, patent expirations, government initiatives, technological advancements, therapeutic expansion, and collaboration. As the demand for cost-effective injectable medications continues to rise, the market for generic injectables is expected to grow, providing healthcare providers and patients with more accessible treatment options.
Introduction
Generic injectables refer to pharmaceutical products that are identical or bioequivalent to brand-name injectable drugs but are marketed under their generic names. These medications are typically administered via injection, either intravenously, intramuscularly, or subcutaneously. Generic injectables offer cost-effective alternatives to brand-name drugs, providing healthcare providers and patients with more affordable treatment options without compromising quality or safety.Key Trends in the Generic Injectables Market
Some key trends involved in the generic injectables market are as follows:- Increasing Demand for Affordable Healthcare: The rising cost of healthcare has led to a growing demand for affordable treatment options, including generic injectables. Healthcare providers and payers are actively seeking cost-saving measures, and the use of generic injectables offers significant savings without compromising patient care
- Patent Expirations and Market Opportunities: The expiration of patents for several widely-used injectable drugs has opened doors for generic manufacturers to enter the market. This has led to increased competition, reduced prices, and expanded access to essential medications
- Government Initiatives and Regulatory Support: Governments worldwide are implementing policies and initiatives to promote the use of generic medications, including injectables. These efforts aim to increase access to affordable healthcare and reduce healthcare expenditure. Regulatory agencies also play a vital role by establishing guidelines and standards for the approval and quality assurance of generic injectables
- Technological Advancements in Manufacturing: Advancements in manufacturing technologies have improved the efficiency and quality of generic injectable production. Advanced manufacturing techniques, such as lyophilization and aseptic processing, ensure the stability, safety, and sterility of generic injectables
- Expansion of Therapeutic Areas: The range of therapeutic areas covered by generic injectables is expanding. While they have traditionally been associated with essential medications like antibiotics and analgesics, generic injectables are now available for a broader range of therapies, including oncology, critical care, cardiovascular, and neurology
- Collaboration and Partnerships: Collaboration between generic pharmaceutical companies, contract manufacturers, and healthcare providers is becoming increasingly common. Such partnerships aim to ensure a stable supply of quality generic injectables and improve patient access to affordable medications
- Rising Demand for Biologics and Biosimilars: The growing demand for biologic drugs has paved the way for the development of biosimilars, which are highly similar but not identical to the original biologic drugs. Biosimilar injectables offer cost savings and expanded treatment options, contributing to the evolving landscape of generic injectables
Generic Injectables Market Segmentations
Market Breakup by Product Type
- Monoclonal Antibodies
- Immunoglobulin
- Cytokines
- Insulin
- Peptide Hormones
- Blood Factors
- Vaccines
- Chemotherapy Agents
- Small Molecules Antibiotics
- Others
Market Breakup by Molecule Type
- Large Molecules
- Small Molecules
Market Breakup by Application
- Oncology
- Infections Diseases
- Diabetes
- Blood Disorders
- Hormonal Disorders
- Musculoskeletal Disorders
- CNS Diseases
- Pain Management
- Cardiovascular Diseases
- Others
Market Breakup by Route of Administration
- Intramuscular
- Intravenous
- Subcutaneous
Market Breakup by Distribution Channel
- Drug Store
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Market Breakup by Region
North America
- United States of America
- Canada
Europe
- United Kingdom
- Germany
- France
- Italy
- Others
Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others
Latin America
- Brazil
- Argentina
- Mexico
- Others
Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
Generic Injectables Market Scenario
The market for generic injectables is a rapidly growing segment within the pharmaceutical industry. Generic injectables are cost-effective alternatives to brand-name injectable drugs, offering healthcare providers and patients more affordable treatment options without compromising quality or safety.The market is driven by several factors, including the increasing demand for affordable healthcare solutions, the expiration of patents for widely-used injectable drugs, and government initiatives promoting the use of generic medications. Healthcare providers and payers are actively seeking cost-saving measures, and generic injectables provide significant savings without compromising patient care.
Overall, the market for generic injectables is driven by the increasing demand for affordable healthcare, patent expirations, government initiatives, technological advancements, therapeutic expansion, and collaboration. As the demand for cost-effective injectable medications continues to rise, the market for generic injectables is expected to grow, providing healthcare providers and patients with more accessible treatment options.
Generic Injectables Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:- Abbott
- B.D
- Novartis AG
- Pfizer Inc
- Baxter
- Gerresheimer AG
- Germany
- AstraZeneca
- Terumo Medical Corporation
- Teva Pharmaceutical Industries Ltd
- Eli Lilly and Company
- Schott AG
- Sanofi
- Johnson & Johnson Private Limited
- Mylan N.V
- West Pharmaceutical Services, Inc
- SHL Medical AG
- Insulet Corporation
- E3D Elcam
- Drug Delivery Devices
- Ypsomed AG
- AbbVie Inc
- Novo Nordisk A/S
Table of Contents
1 Preface
3 Global Generics Injectable Market Overview
4 Global Generics Injectable Market Landscape
5 Global Generics Injectable Market Dynamics
6 Global Generics Injectable Market Segmentation
7 North America Generics Injectable Market
8 Europe Generics Injectable Market
9 Asia Pacific Generics Injectable Market
10 Latin America Generics Injectable Market
11 Middle East and Africa Generics Injectable Market
12 Patent Analysis
13 Grants Analysis
14 Funding Analysis
15 Partnership and Collaborations Analysis
16 Regulatory Framework
17 Supplier Landscape
18 Global Generics Injectable Market- Distribution Model (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
21 Pricing Models and Strategies (Additional Insight)
Companies Mentioned
- Abbott
- B.D.
- Novartis AG
- Pfizer Inc.
- Baxter
- Gerresheimer AG
- Germany
- AstraZeneca
- Terumo Medical Corporation
- Teva Pharmaceutical Industries Ltd.
- Eli Lilly and Company
- Schott AG
- Sanofi
- Johnson & Johnson Private Limited
- Mylan N.V.
- West Pharmaceutical Services Inc.
- SHL Medical AG
- Insulet Corporation
- E3D Elcam
- Drug Delivery Devices
- Ypsomed AG
- AbbVie Inc.
- Novo Nordisk A/S
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 147 |
| Published | May 2023 |
| Forecast Period | 2023 - 2031 |
| Estimated Market Value ( USD | $ 115.1 Billion |
| Forecasted Market Value ( USD | $ 305.5 Billion |
| Compound Annual Growth Rate | 13.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
